- Tirzepatide is the first dual GIP/GLP-1 agonist — a next-generation molecule after Semaglutide
- Research Tirzepatide is no longer offered by any verified supplier (CertaPeptides, SwissChems, AminoClub) since its delisting mid-2026: no verified purchase option remains
- The available and verified GLP-1 research alternative is Retatrutide — a triple GIP/GLP-1/glucagon agonist, the next generation after tirzepatide
- Retatrutide at CertaPeptides (EU): from 44.49 EUR/5mg, purity >=98% HPLC, independent certificate of analysis (Janoshik/Finnrick) included, strictly for research only
Our Quick Recommendation
Looking for Tirzepatide for research? Here's an important point to know: since mid-2026, research tirzepatide is no longer listed by any verified supplier (a withdrawal most likely tied to its commercialization by Eli Lilly). There is currently no verified purchase option for this molecule.
The only GLP-1 research molecule still available at our verified European supplier is Retatrutide, a triple agonist of the GIP / GLP-1 / glucagon receptors — the next generation after the dual-agonist tirzepatide.
| Molecule | Region | Supplier | Price 5mg | Shipping | Action |
|---|---|---|---|---|---|
| Retatrutide (GLP-1 alternative) | Europe | CertaPeptides | from 44.49 EUR | 3-7 days | Order Retatrutide |
| Tirzepatide | All regions | No longer available at verified suppliers (delisted mid-2026) | |||
Important: Retatrutide is a compound strictly intended for in vitro research, not for human consumption. For other verified research peptides, see also BPC-157.
What is Tirzepatide?
Tirzepatide is a synthetic peptide of 39 amino acids developed by Eli Lilly. It's the first dual GIP and GLP-1 receptor agonist, representing a major advancement over simple GLP-1 agonists like semaglutide.
Key Characteristics
- Dual incretin action — Simultaneously activates GIP and GLP-1 receptors
- Next generation — Superior efficacy to semaglutide in comparative studies (SURPASS-2)
- Significant weight loss — Up to 20-22% body weight loss in SURMOUNT trials
- Weekly administration — One injection per week due to its long half-life
Brand Names
Tirzepatide is marketed under two brands depending on the indication:
- Mounjaro — For type 2 diabetes
- Zepbound — For weight management
These pharmaceutical versions require a medical prescription. Tirzepatide as a research peptide is no longer offered by verified suppliers today. To learn more about this molecule, see our complete Tirzepatide guide.
CertaPeptides — Verified GLP-1 Alternative (Retatrutide)
CertaPeptides no longer offers research tirzepatide since its delisting mid-2026. However, this verified European supplier (based in Romania) still offers Retatrutide, the only GLP-1 research molecule still available from a verified source.
Strengths
- Cutting-edge GLP-1 alternative — Retatrutide is a triple GIP / GLP-1 / glucagon agonist
- Guaranteed purity — HPLC tests >=98%, independent certificate of analysis (Janoshik/Finnrick, 99.90% HPLC)
- Fast European shipping — 3-7 business days within the EU
- Transparent pricing — from 44.49 EUR/5mg (variants up to 50mg), no hidden fees
- Secure payment — Credit card and crypto accepted
Considerations
- Europe shipping only (27 EU countries)
- Return policy limited to 14 days
- Compound strictly intended for in vitro research
Retatrutide Available
| Product | Dosage | Price | Link |
|---|---|---|---|
| Retatrutide | 5mg | from 44.49 EUR | Order Retatrutide |
Verified GLP-1 alternative: since research tirzepatide is no longer listed, Retatrutide is the reliable GLP-1 option at CertaPeptides in Europe.
Browse Available GLP-1 at CertaPeptidesWhy is Tirzepatide No Longer Available?
Unlike established peptides like BPC-157 or TB-500, research Tirzepatide has been fully delisted at verified suppliers mid-2026. Several factors explain this withdrawal:
1. Likely Regulatory Withdrawal
Since tirzepatide is now a molecule widely commercialized by Eli Lilly (Mounjaro, Zepbound), its availability as a research peptide was pulled from the catalogs of verified suppliers mid-2026. The old product URLs now redirect to the category page.
2. Synthesis Complexity
Tirzepatide is a 39 amino acid peptide with an acylation modification (C20 fatty acid chain). This complex structure makes its synthesis difficult and expensive.
3. Active Patents and Pharmaceutical Demand
Eli Lilly holds patents on Tirzepatide, and global demand for Mounjaro and Zepbound is enormous (over $10 billion in annual sales), which limits research supply.
Tirzepatide Status at Verified Suppliers
| Supplier | Tirzepatide Status | Available GLP-1 Research Molecule |
|---|---|---|
| CertaPeptides | Delisted (mid-2026) | Retatrutide |
| SwissChems | Not available | No verified GLP-1 research molecule |
| AminoClub | Not available | GHK-Cu (non-GLP-1) |
Since research tirzepatide is no longer available at any verified source, Retatrutide (triple GIP/GLP-1/glucagon agonist) is the available and verified GLP-1 research alternative at CertaPeptides in Europe.
How to Verify the Quality of a GLP-1 Research Peptide
Whether it's tirzepatide (now unavailable) or its alternative retatrutide, it's crucial to verify quality before purchasing. Here are the essential criteria:
1. Certificate of Analysis (CoA)
A valid CoA must include:
- HPLC chromatogram — Purity >=98%
- Mass spectrometry (MS) — Confirmation of molecular weight
- Amino acid sequence — Verification of the full sequence
- Batch number — Matching the received product
For reference, tirzepatide is a 39 amino acid peptide with a molecular weight of 4813.45 g/mol.
2. Realistic Pricing
GLP-1 peptides are expensive to produce. A price that's "too good to be true" is a major red flag. Verified Retatrutide at CertaPeptides is offered from 44.49 EUR/5mg; be wary of abnormally low prices or unverified sources.
3. Storage and Shipping
These peptides are temperature sensitive. Verify:
- Storage at -20C before shipping
- Shipping with ice packs
- Insulated packaging
4. Supplier Reputation
Look for independent reviews on Reddit, specialized forums, and check the supplier's track record.
Our verified GLP-1 research alternative:
- Europe: Retatrutide at CertaPeptides (from 44.49 EUR/5mg, independent CoA included)
Tirzepatide Buying FAQ
Recommended products
Research peptides selected for quality and purity:
Retatrutide
Metabolic Peptide
Test your knowledge
Quick quiz · 6 questions
Peptide Lab — free calculator & tracker
Calculate your reconstitution, track your peptides and injections. Free, no credit card required.
Frequently Asked Questions
Can you still buy research Tirzepatide?
What's the difference between research Tirzepatide and Mounjaro?
What is Retatrutide and why is it offered as an alternative?
Can I buy Tirzepatide in the USA?
How should I store Tirzepatide after receiving it?
Is Tirzepatide more effective than Semaglutide?
Sources
- Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.
- Frias JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.
- Nauck MA, D'Alessio DA (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Cardiovascular Diabetology.